It is probable that some downstream targets of this pathway are very strong inducers of tumor cell survival (i.e., COX-2 and survivin), yet completely abolishing this pathway has not produced convincing evidence that pharmacological inhibition is feasible in combination with PDT. The gene discussed is PTGS2; the disease is neoplasm.